<!DOCTYPE html>
<html>
<head>
<meta charset="utf-8"/>
<meta content="width=device-width, initial-scale=1.0" name="viewport"/>
<link href="../../../webpages.css" rel="stylesheet"/>
</head>
<body>
<div class="banner">
<div class="banner-content">
<h1>DermpathNet</h1>
</div>
</div>
<nav>
<a href="../../../index.html" target="_blank">
<text type="button">Home</text>
</a>
<a href="../../../browser-page-317.html" target="_blank">
<text type="button">Browse</text>
</a>
<a href="../../../download-page.html" target="_blank">
<text type="button">Downloads</text>
</a>
<a href="../../../contact-us.html" target="_blank">
<text type="button">About</text>
</a>
</nav>
<footer class="site-footer">
<p>@2024 New York University Grossman School of Medicine, Weill Cornell Medicine</p>
<!--<p>Privacy Policy | Terms of Service | Cookie Policy</p>-->
</footer>
<title>Clinicopathologic study of E-cadherin/beta-catenin complex, and topoisomerase-II in a series of 71 liposarcoma cases.-DermPath</title>
<div class="content-container"> <div class="figures-container"> <div class="image-side"> <img alt="Clinicopathologic study of E-cadherin/beta-catenin complex, and topoisomerase-II in a series of 71 liposarcoma cases." class="clickable-image" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d449/3293059/196c2c2abe0f/1477-7819-10-28-1.jpg"/> </div> <div class="text-side"> <h1>Clinicopathologic study of E-cadherin/beta-catenin complex, and topoisomerase-II in a series of 71 liposarcoma cases.</h1> <p>a) Retroperitoneal pleomorphic liposarcoma (H&amp;E x400) b) Weak expression of beta-catenin in pleomorphic retroperitoneum liposarcoma (&lt; 20% of neoplastic cells showed cytoplasmic immunoreactivity (long arrow) and &lt; 5% nuclear immunoreactivity (short arrow) (DAB X400)). c) Weak expression of beta-catenin in extremity liposarcoma ((&lt; 20% of neoplastic cells showed cytoplasmic immunoreactivity (long arrow) and &lt; 5% nuclear immunoreactivity (short arrow) (DAB x400). d) Area with extensive membranous and cytoplasmic expression of beta-catenin in an extremity liposarcoma ((&lt; 50% of neoplastic cells showed cytoplasmic and membranous immunoreactivity (long arrow) (DAB x400)).</p> <p>PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/22300273/" target="_blank">22300273</a></p><p>Type: Premalignant/Malignant, Category: Adipocytic</p>
</div> </div></div></body></html>